CAJ | 학술논문

目的：：探讨氨磺必利治疗慢性精神分裂症患者的疗效与安全性。方法：将80例慢性精神分裂症患者随机分为氨磺必利组和喹硫平组,每组40例,分别给予患者氨磺必利和喹硫平治疗,疗程12周。于治疗前和治疗2、4、8、12周,采用阳性和阴性症状量表( PANSS)、临床疗效总评量表( CGI-SI)评定两组患者的临床疗效；不良反应量表( TESS)、锥体外系副反应量表( RSESE)评定两组患者的不良反应。结果：两组患者的显效率(P>0.05)和有效率(P>0.05)差异无统计学意义；治疗2周,氨磺必利组患者的阳性症状分、阴性症状分、PANSS总分及CGI-SI评分较治疗前显著降低(P<0.05或P<0.001)；喹硫平组患者则于治疗4周,PANSS总分及各因子分、CGI-SI评分较治疗前显著降低(P<0.05或P<0.001)；治疗4周(P<0.05)、8周(P<0.05)、12周(P<0.05),氨磺必利组患者的PANSS阴性症状分明显优于喹硫平组；两组患者的不良反应较少。结论：氨磺必利治疗慢性精神分裂症患者安全有效。
목적：：탐토안광필리치료만성정신분렬증환자적료효여안전성。방법：장80례만성정신분렬증환자수궤분위안광필리조화규류평조,매조40례,분별급여환자안광필리화규류평치료,료정12주。우치료전화치료2、4、8、12주,채용양성화음성증상량표( PANSS)、림상료효총평량표( CGI-SI)평정량조환자적림상료효；불량반응량표( TESS)、추체외계부반응량표( RSESE)평정량조환자적불량반응。결과：량조환자적현효솔(P>0.05)화유효솔(P>0.05)차이무통계학의의；치료2주,안광필리조환자적양성증상분、음성증상분、PANSS총분급CGI-SI평분교치료전현저강저(P<0.05혹P<0.001)；규류평조환자칙우치료4주,PANSS총분급각인자분、CGI-SI평분교치료전현저강저(P<0.05혹P<0.001)；치료4주(P<0.05)、8주(P<0.05)、12주(P<0.05),안광필리조환자적PANSS음성증상분명현우우규류평조；량조환자적불량반응교소。결론：안광필리치료만성정신분렬증환자안전유효。
Objective:To explore efficacy and safety of Amisulpride in treatment of chronic schizophrenia. Methods:80 pa-tients with chronic schizophrenia were randomly assigned to Amisulpride group (n=40) and Quetiapine group (n=40) and treated for 12 weeks. Positive and negative symptom scale ( PANSS) , clinical global impression-severity scale ( CGI-SI) were used to evaluate the efficacy;treatment emergent symptom scale ( TESS) and rating scale for extrapyramidal side effects ( RSESE) were used to meas-ure the side effect before and 2, 4, 8 and 12 weeks after the treatment. Results:There were no significant differences in the obvious effective rate (P>0. 05) and the effective rate (P>0. 05) between the two groups. From the 2nd week, the total scores of PANSS, positive symptom scores, negative symptoms scores and CGI-SI scores of Amisulpride group decreased more remarkably than those be-fore the treatment (P<0. 05 or P<0. 001). From the 4th week, the total and factor scores of PANSS and CGI-SI scores of Quetiapine group decreased more remarkably than those before the treatment (P<0. 05). At the end of the 4th (P<0. 05), 8th (P<0. 05), and 12th (P<0. 05) week, the negative symptoms scores of Amisulpride group were obviously better than those of Quetiapine group. Both groups had fewer adverse reactions. Conclusions:Amisulpride is an effective and safe drug in the treatment of chronic schizophrenia.